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Malignant Hyperthermia

Nicholas Colangelo, BSN, RN, CCRN
Otterbein University, Westerville, Ohio
Introduction
Malignant hyperthermia is an abnormal
systemic response to volatile anesthetics
and a certain depolarizing neuromuscular
blocking drug that causes an uncontrollable
release of intracellular calcium ions from
the sarcoplasmic reticulum. This reaction
subsequently causes sustained muscle
contraction, over-utilization of the body’s
energy stores, and an increase in lactic acid
production from anaerobic
hypermetabolism, all of which can cause
rapid death if not promptly treated. Due to
the extreme rarity of malignant
hyperthermia susceptibility and the even
rarer occurrence of the manifested state, it
is a pathophysiologic condition that many
in the medical field are unfamiliar with.
Unfamiliarity breeds discomfort.
Discomfort in the healthcare setting can
lead to ineffective and erroneous patient
care. Therefore, the topic of this
pathophysiology poster is malignant
hyperthermia and its purpose is to further
aid in spreading awareness of malignant
hyperthermia and educate colleagues in
the recognition and treatment of malignant
hyperthermia. It is of extreme importance
that perioperative nurses, especially nurse
anesthetists, are comfortable with
recognizing and treating malignant
hyperthermia if it were ever to occur in the
healthcare setting.

Pathophysiological Processes
Pathophysiology:
•
Predisposition to MH is based on
genetics, specifically an autosomal
dominant disorder involving the
mutation of the type 1: RyR1
(ryanodine receptor) or
dihydropyridine receptor (Mullins,
2018)
•
The mutation causes
hypermetabolism and an unabated
and abnormal release of calcium
ions from the sarcoplasmic
reticulum inside muscle cells when
exposed to MH-triggering agents
(Mullins, 2018)
•
Atypical release of intracellular
calcium causes an increased and
sustained actin-myosin interaction
(Riazi & Brandom, 2015)
•
Mutated receptor prevents the
sarcolemmal sodium-calcium
pump from restoring homeostasis
by reincorporating calcium via
aerobic metabolism (Kim et al.,
2019)
•
MH-triggering agents include
volatile anesthetic gases
(desflurane, isoflurane,
sevoflurane, and halothane) and
depolarizing muscle relaxants
(succinylcholine) (Mullins, 2018)
•
MH can be triggered by heat and
intense exercise (Mullins, 2018)

Signs & Symptoms:
•
Muscle rigidity
•
Increased core temperature
•
Increased production of carbon
dioxide
•
Increased rate of oxygen
consumption
•
Unexplained tachycardia
(Kim et al., 2019)
Late Signs:
•
Hyperkalemia
•
Acidosis
•
Myoglobinuria
•
Increased creatine kinase
•
Electrolyte imbalances
•
Congestive heart failure
•
Pulmonary edema
•
Congestive heart failure
•
Alterations in consciousness
(Kim et al., 2019)
Complications:
•
Cardiac arrhythmias and
dysfunctions
•
Renal failure
•
Disseminated intravascular
coagulation (DIC)
•
Central nervous system injury
•
Death
(Riazi & Brandom, 2015)

Implications for Nursing Care

Treatment
•

Preoperative:
•
Perform comprehensive history
•
MH-susceptibility can be
phenotyped via caffeine-halothane
muscle contracture tests (CHCT)
(Mullins, 2018)
•
All perioperative patients should be
screened for MH history in self and
family
•
MH screening should help guide
plan of care (Miller, 2017)
•
All perioperative patients who have
a family history of possible MH
susceptibilities may benefit from
being screened prior to receiving
general anesthesia
•
MH may develop after first
exposure, but more commonly after
three anesthetic exposures (Kim et
al., 2019)
Intraoperative:
•
MH episodes may resemble sepsis,
pheochromocytoma, neuroleptic
malignant syndrome, serotonin
syndrome, and thyroid storm differentiation is critical (Kim et al.,
2019)

Figure 1: (Mullins, 2018, p.
583)

Figure 2: (Mullins, 2018, p.
584)

Monitoring should always include, but
not be limited to: continuous
temperature, heart rate, oxygen
saturation, blood pressure, and endtidal carbon dioxide monitoring
(Mullins, 2018)
•
Know where designated MH supplies
is stocked on the unit; consider
dedicating a specific cart for the
supplies if one does not already exist
•
Know the facilities recommended
treatment guidelines for MH
•
Local anesthestics and/or
spinal/epidural blocks are safe
alternatives to general anesthesia in
MH-susceptible patients (Riazi &
Brandom, 2015)
Postoperative:
•
Transfer patient to critical care
•
Recrudescence of MH may occur after
symptoms have resolved, close
monitoring is recommended for
multiple days (Kim et al., 2019)
•

•

•

•
•

•

Removal and cessation of all
potential triggers (Riazi & Brandom,
2015)
Abort surgery and close all incisions
as soon as safely possible (Mullins,
2018)
If surgery cannot be safely stopped,
begin nontriggering anesthetics
intravenously (Kim et al., 2019)
Call Malignant Hyperthermia
Association (MHAUS) hotline (Kim
et al., 2019)
Hyperventilate patient and utilize
inline charcoal filters (if available)
to remove trace gases from
breathing circuit (Bilmen &
Hopkins, 2019)
Dantrolene (a muscle relaxant that
antagonizes the ryanodine receptor,
slowing the release of calcium) to
be given 2.5mg/kg intravenously,
with a maximum dose of 10mg/kg
(Kim et al., 2019)

•

•

•

•

•

•

Draw laboratories as soon as
possible: arterial blood gas (ABG),
complete metabolic panel, complete
blood count, urine myoglobin
Repeat creatine kinase (CK) levels
and ABG analyses until acidosis and
rhabdomyolysis resolves (Kim et al.,
2019)
Actively cool patient to less than 38
degrees Celsius with whatever
appropriate methods are available
(Kim et al., 2019)
Treat hyperkalemia with calcium,
glucose, insulin, and bicarbonate
when necessary (Kim et al., 2019)
Avoid calcium channel blockers
when treating potential
arrhythmias (can precipitate
hyperkalemia) (Kim et al., 2019)
Fluid resuscitation to achieve a
urine output of greater than 1
ml/kg/h (Kim et al., 2019)

Conclusions
MH is estimated to occur in only 1 in
15,000 children and only 1 in 50,000
adults who are exposed to
anesthesia, yet it is estimated that
somewhere between 1 in 2000 and 1
in 3000 are susceptible to MH (Kim et
al., 2019). MH poses an immediate
threat to all healthcare facilities
delivering anesthesia. It is the sole
responsibility of the nursing team to
ensure their facility and staff is well
equipped and capable of promptly
recognizing and treating MH episodes
in the susceptible minority. Through
vigilance and ongoing education, MH
fatalities can be significantly reduced.
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